CONTINGENT FORWARD CONTRACTS - Narrative (Details) - USD ($)			1 Months Ended									2 Months Ended	3 Months Ended		6 Months Ended			12 Months Ended
		Dec. 24, 2020	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Oct. 31, 2019	Apr. 30, 2019	Apr. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Apr. 01, 2021	Sep. 30, 2018
Forward Contract Indexed to Issuer's Equity [Line Items]
Issuance of convertible preferred shares (in shares)	[1]													66,909,408
Contingent forward contract liability, fair value loss															$ 0	$ 454,546,000
Issuance of Series E convertible preferred stock														$ 1,361,273,000
Change in fair value of forward contracts													$ 0	$ (12,382,000)	0	(454,546,000)
Stock price (in dollars per share)																					$ 23.78
Eligible Holders
Forward Contract Indexed to Issuer's Equity [Line Items]
Aggregate value of convertible preferred shares approved for issuance					$ 71,000,000
Series D
Forward Contract Indexed to Issuer's Equity [Line Items]
Proceeds from issuance of convertible preferred stock								$ 200,000,000	$ 200,000,000	$ 400,000,000	$ 200,000,000				0	3,000,000
Issuance of convertible preferred shares (in shares)								82,496,121	82,496,092										374,777,280
Settlement of Series D contingent forward contract liability								$ 21,384,000	$ 18,180,000
Preferred stock, price (in dollars per share)																			$ 2.33
Series E
Forward Contract Indexed to Issuer's Equity [Line Items]
Proceeds from issuance of convertible preferred stock		$ 400,000,000	$ 92,900,000	$ 107,100,000	$ 400,000,000	$ 400,000,000	$ 500,000,000					$ 200,000,000			$ 0	$ 600,000,000
Issuance of convertible preferred shares (in shares)		133,818,821	66,909,408		133,818,821		167,273,525									200,728,229	[2]
Preferred stock, price (in dollars per share)			$ 2.99		$ 2.99		$ 2.99					$ 2.99
Issuance of Series E convertible preferred stock					$ 400,000,000											$ 3,206,159,000
Series E | Eligible Holders
Forward Contract Indexed to Issuer's Equity [Line Items]
Preferred stock, price (in dollars per share)					$ 2.99
Convertible preferred shares approved for issuance (in shares)					23,737,221
Series E | Additional Purchasers
Forward Contract Indexed to Issuer's Equity [Line Items]
Preferred stock, price (in dollars per share)					$ 2.99
Series E | Management
Forward Contract Indexed to Issuer's Equity [Line Items]
Issuance of convertible preferred shares (in shares)												3,034,194
Series E | Director
Forward Contract Indexed to Issuer's Equity [Line Items]
Issuance of convertible preferred shares (in shares)												1,658,705
Series E | Chief Executive Officer
Forward Contract Indexed to Issuer's Equity [Line Items]
Issuance of convertible preferred shares (in shares)			535,275
Series D Contingent Forward Contract Liability
Forward Contract Indexed to Issuer's Equity [Line Items]
Debt discount to the convertible notes																						$ 18,600,000
Contingent forward contract, fair value						0			36,400,000									$ 0
Contingent forward contract reclassified to preferred shares									$ 18,200,000
Settlement of Series D contingent forward contract liability								$ 39,600,000
Contingent forward contract liability, fair value loss																		8,700,000
Series E Contingent Forward Contract Liability
Forward Contract Indexed to Issuer's Equity [Line Items]
Contingent forward contract, fair value		$ 110,500,000	$ 722,400,000		$ 1,444,900,000	110,500,000	$ 800,000					$ 722,400,000						110,500,000		$ 0
Contingent forward contract reclassified to preferred shares			$ 1,200,000,000
Contingent forward contract liability, fair value loss						$ (109,700,000)												$ 109,700,000

[1] The number of shares of convertible preferred stock and common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 “Description of Business” and Note 3 “Reverse Capitalization” for more information.

[2] The number of shares of convertible preferred stock and common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 - Description of Business and Note 3 - Reverse Capitalization for more information.